Pixee Medical Announces the Commercial Launch of Knee+ in the USA

The first augmented reality (AR) guidance system for total knee arthroplasty will be launched in the USA at the American Association of Orthopaedic Surgeons (AAOS) Annual Meeting on March 22-26 in Chicago.

Pixee Medical, a pioneer in augmented surgical guidance technology, has announced that its Knee+ AR computer-assisted orthopedic solution is going to be commercially available in the USA with a perfect fit for Ambulatory Surgical Centers (ASCs) need.

Pixee Medical notes Knee+ is a patented platform designed to help orthopedic surgeons perform surgery through the real-time 3D positioning of instruments, right in their field of view. Knee+ is intuitive and consists of proprietary software using a unique proprietary tracking system running on off-the-shelf smart glasses, with no bulky capital equipment or disposables required.

View video here.

This solution was launched commercially in January 2021 in Europe and Australia. In the challenging COVID context, without any commercial promotion, the product was quickly adopted, with more than 100 systems sold thanks to an easy-to-use and scalable solution.

“Since our first surgery in the USA in Boston in October 2021, we have organized a successful round of surgeries on multiple clinical sites across the USA. We are now ready and confident to launch the product in the leading worldwide market for orthopedics” states Sébastien Henry, Founder and CEO of Pixee Medical. “Our solution is the only imageless & open platform for total knee surgery available in the US.”

“We will be at the AAOS Meeting to meet with surgeons and finalize the organization of our distribution channel.”

Pixee will soon be adding new features to its Knee+ platform, with soft tissue balancing, kinematic alignment and data connectivity. It will also be expanding its portfolio with a mixed reality product for total shoulder arthroplasty and with an easy-to-use cup orientation and leg length controlling AR tool for total hip arthroplasty. Knee+ is now compatible with surgical hoods.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”